Samira Asgari, PhD
- ASSISTANT PROFESSOR | Genetics and Genomic Sciences
Research Topics:Computational Biology, Gene Expressions, Genomics, Human Genetics and Genetic Disorders, Immunology, Infectious Disease, Personalized Medicine
I started my research group at Mount Sinai in 2022. In my group, we focus on understanding the human genetic basis of infection and immunity. Some of the questions we ask include: What are the human genetic variants underlying susceptibility and resistance to specific pathogens? What are the molecular mechanisms connecting these variants to cellular functions and immune responses? and How do differences in population history and demography play into susceptibility and resistance to specific pathogens? We use a combination of statistical, functional, and population genomics methods to answer these questions. For a list of current projects check our lab website.
I completed my undergraduate and M.Sc. studies at the University of Tehran, Iran; my Ph.D. at EPFL, Switzerland (Jacques Fellay lab); and my postdoctoral training at Brigham and Women's Hospital in Boston (Soumya Raychaudhuri lab).
In my spare time, I love to read, hike, taste cheese, and draw.
Multi-Disciplinary Training AreasGenetics and Genomic Sciences [GGS], Immunology [IMM]
BSc, University of Tehran
MSc, University of Tehran
PhD, École polytechnique fédérale de Lausanne (EPFL)
postdoc, Harvard Medical School
Nature Research Awards for Inspiring and Innovating Science
NIH T32 Training Grant in Precision and Genomic Medicine
10X Genomics single-cell genomics scientific challenge grant
Advanced Postdoc.Mobility grant
ASHG Charles J. Epstein Award for Excellence in Human Genetics Research – Finalist
International Primary Immunodeficiencies Congress
Early Postdoc.Mobility grant
Human genomics of infectious diseases; Human Statistical and Population genomics; Immunogenomics
Infectious diseases are one of the leading causes of mortality and morbidity worldwide. While many old infections like tuberculosis and HIV still claim millions of lives every year globally. New and emerging infections are also becoming a growing threat due to population growth, urbanization of animal habitats, global warming, and rapid population movement. There is thus a pressing need for a better understanding of infectious disease biology and for the development of innovative diagnoses, preventive, and therapeutic measures to combat ongoing and future outbreaks. Previous studies, including my PhD work, have highlighted a key role for human genetic variation in determining the outcome of infectious diseases. My previous work also shows that many disease-associated variants, including the ones affecting infection outcome, can exert their effect by regulation of cellular processes such as gene expression. Together, these studies have established that susceptibility to infectious diseases is a heritable trait, led to the discovery of several key genes that can cause susceptibility to different pathogens, and identified many genomic loci that can modulate the infectious disease risk. However, human genomics of infectious diseases lags behind other complex traits in terms of the number of loci identified. Additionally, for most known infectious diseases risk loci the cellular function of the variants and the biological mechanisms by which they influence disease pathogenesis are not known. Finally, even though the burden of infectious diseases is highest in non-European populations, the majority of large-scale infectious disease genomics studies are done in populations of European ancestry. As shown by my postdoctoral work, ancestry differences can lead to variations in the outcome of complex traits including infectious diseases and might explain why there is little concordance between infectious disease risk loci identified in different populations. There is thus a need to expand human genomics studies of infectious diseases to understudied populations and to use new approaches to connect genetic variants to their molecular function in the disease-relevant context. To this end, my group uses a combination of statistical, functional, and population genomics methods to understand how human genetic diversity translates to phenotypic diversity in the immune system and how this phenotypic diversity affects the clinical outcome of infectious diseases.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Asgari during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Varaint Bio; biogen
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.